ENDRA Life Sciences Inc (NDRA)
NASDAQ:NDRA
Want to see NDRA full AI Analyst Report?
Top Page
ENDRA Life Sciences
(NASDAQ:NDRA)
Select Model
Select Model
Rating:46Neutral
Price Target:
$4.00
▼(-14.71% Downside)
Action:Reiterated
Date:05/28/26
The score is primarily constrained by very weak financial performance (no revenue, sizable losses, and continued cash burn with shrinking equity). Technicals are moderately supportive with price above key moving averages and neutral momentum, but valuation is limited by negative earnings, and corporate events remain mixed due to financing tied to compliance pressure and restructuring/strategic review.
Positive Factors
Proprietary TAEUS technology
ENDRA's TAEUS (ENDRA Nexus) is a differentiated, device-based diagnostic platform focused on liver steatosis and fibrosis imaging. A proprietary, device-centric product offers durable IP and commercialization pathways (device sales, service, research placements) that can support repeatable revenue once clinical adoption and placements scale.
Negative Factors
No revenue base
The company has not established a repeatable revenue stream, reporting zero revenue while incurring substantial TTM losses. Absent demonstrable device placements or recurring services, it's difficult to model organic growth or margin sustainability, making long-term viability dependent on financing or strategic transactions.
Read all positive and negative factors
Positive Factors
Negative Factors
Proprietary TAEUS technology
ENDRA's TAEUS (ENDRA Nexus) is a differentiated, device-based diagnostic platform focused on liver steatosis and fibrosis imaging. A proprietary, device-centric product offers durable IP and commercialization pathways (device sales, service, research placements) that can support repeatable revenue once clinical adoption and placements scale.
Read all positive factors
ENDRA Life Sciences (NDRA) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$5.32M
Dividend YieldN/A
Average Volume (3M)514.97K
Price to Earnings (P/E)―
Beta (1Y)1.30
Revenue GrowthN/A
EPS Growth98.32%
CountryUS
Employees21
SectorHealthcare
Sector Strength45
IndustryMedical - Diagnostics & Research
Share Statistics
EPS (TTM)-8.16
Shares Outstanding1,270,077
10 Day Avg. Volume1,472,495
30 Day Avg. Volume514,968
Financial Highlights & Ratios
PEG Ratio0.04
Price to Book (P/B)1.58
Price to Sales (P/S)0.00
P/FCF Ratio-0.69
Enterprise Value/Market Cap0.80
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-106.87
Enterprise Value/Ebitda-0.67
Forecast
1Y Price Target
$25.00Price Target Upside433.05% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)-4.65
Revenue Forecast (FY)$100.00K
ENDRA Life Sciences Business Overview & Revenue Model
Company Description
ENDRA Life Sciences Inc. specializes in advancing the capabilities of clinical diagnostic ultrasound. The company's primary development is thermo-acoustic enhanced ultrasound technology, which operates by emitting sound waves that echo off interna...
How the Company Makes Money
ENDRA Life Sciences generates revenue primarily through the development and commercialization of its TAEUS-based imaging system(s). Its revenue model is centered on selling (or potentially placing) imaging devices to hospitals, clinics, and resear...
ENDRA Life Sciences Earnings Call Summary
Earnings Call Date:Aug 22, 2024
(Q2-2024)
| % Change Since: |
Next Earnings Date:Aug 17, 2026
Earnings Call Sentiment Neutral
The earnings call presented several strategic initiatives aimed at improving ENDRA's focus and operational efficiency, alongside positive developments in management, regulatory strategy, and intellectual property. However, financial challenges and stock performance issues remain concerns.Positive Updates
Enhanced Management Team
ENDRA has strengthened its management team by adding two experienced operators: Richard Jacroux as CFO and Ziad Rouag as Head of Clinical and Regulatory Affairs, both bringing significant expertise in transforming technology companies and navigating regulatory processes.
Negative Updates
Reverse Stock Split Challenges
The reverse stock split intended to maintain NASDAQ listing was derailed by high volume of exercised warrants, resulting in trading below $1, creating uncertainty for the company's stock performance.
Read all updates
Q2-2024 Updates
Positive
Negative
Enhanced Management Team
ENDRA has strengthened its management team by adding two experienced operators: Richard Jacroux as CFO and Ziad Rouag as Head of Clinical and Regulatory Affairs, both bringing significant expertise in transforming technology companies and navigating regulatory processes.
Read all positive updates
Company Guidance
During the ENDRA Life Sciences Q2 2024 earnings call, significant guidance was provided by the management team, outlining various strategic initiatives. Notably, the company has completed a 1-for-50 reverse stock split aimed at maintaining its NASDAQ listing, though recent high warrant exercise volumes have impacted their stock price adversely. Six key operational changes were introduced, including the enhancement of the management team with the addition of a seasoned CFO and a new Head of Clinical and Regulatory Affairs. The company plans to conduct a statistically-powered multicenter prospective clinical trial, expanding the number of subjects from 20 to 250. The financial update revealed a $7.3 million net raise from a public offering, with operating expenses reduced by 26% on an annual basis. ENDRA's goal is to complete clinical work and submit a de novo application to the FDA by mid-2025, with the current cash runway projected to fund the company into the first half of 2025. The management reiterated their confidence in ENDRA's technology and market potential, highlighting ongoing efforts to formalize a long-term business strategy and improve financial execution.ENDRA Life Sciences Financial Statement Overview
Summary
Income Statement
6
Very Negative
Balance Sheet
34
Negative
Cash Flow
10
Very Negative
| Breakdown | Mar 2026 | Mar 2025 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| EBITDA | -5.61M | -10.61M | -10.25M | -12.92M | -11.27M |
| Net Income | -7.03M | -11.51M | -10.06M | -13.18M | -11.23M |
Balance Sheet | |||||
| Total Assets | 3.85M | 4.45M | 6.75M | 9.27M | 12.87M |
| Cash, Cash Equivalents and Short-Term Investments | 762.37K | 3.23M | 2.83M | 4.89M | 9.46M |
| Total Debt | 492.35K | 584.42K | 394.40K | 546.63K | 796.09K |
| Total Liabilities | 1.59M | 1.89M | 1.10M | 2.07M | 2.09M |
| Stockholders Equity | 2.26M | 2.56M | 5.66M | 7.20M | 10.78M |
Cash Flow | |||||
| Free Cash Flow | -5.20M | -7.42M | -9.58M | -12.97M | -11.17M |
| Operating Cash Flow | -5.18M | -7.40M | -9.55M | -12.77M | -11.12M |
| Investing Cash Flow | -3.02M | -12.80K | -24.72K | -202.58K | -45.00K |
| Financing Cash Flow | 5.73M | 7.81M | 7.52M | 8.40M | 13.40M |
ENDRA Life Sciences Technical Analysis
Negative
4.69
Price Trends
5.10
Negative
4.47
Negative
4.88
Negative
Market Momentum
-0.20
Positive
36.58
Neutral
5.50
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For NDRA, the sentiment is Negative. The current price of 4.69 is below the 20-day moving average (MA) of 5.13, below the 50-day MA of 5.10, and below the 200-day MA of 4.88, indicating a bearish trend. The MACD of -0.20 indicates Positive momentum. The RSI at 36.58 is Neutral, neither overbought nor oversold. The STOCH value of 5.50 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for NDRA.
ENDRA Life Sciences Risk Analysis
ENDRA Life Sciences disclosed 46 risk factors in its most recent earnings report. ENDRA Life Sciences reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
ENDRA Life Sciences Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
46 Neutral | $5.32M | -0.69 | -537.60% | ― | ― | 98.32% | |
44 Neutral | $5.62M | -0.32 | -174.16% | ― | 33.26% | 49.65% | |
43 Neutral | $3.60M | -0.14 | -259.18% | ― | -44.78% | 92.56% | |
43 Neutral | $3.85M | ― | -496.37% | ― | -87.25% | 87.10% |
* Healthcare Sector Average
NDRA
ENDRA Life Sciences
4.19
0.82
24.33%
BNBX
BNB Plus
0.50
-4.15
-89.24%
INBS
Intelligent Bio Solutions
2.35
-17.45
-88.13%
ISPC
iSpecimen
2.68
-46.92
-94.60%
BGLC
BioNexus Gene Lab Corp
1.97
-1.01
-33.89%
ENDRA Life Sciences Corporate Events
Business Operations and StrategyDelistings and Listing ChangesPrivate Placements and FinancingRegulatory Filings and Compliance
ENDRA Life Sciences Announces Strategic Private Placement Financing
Positive
May 28, 2026
On May 27, 2026, ENDRA Life Sciences entered into a private placement securities purchase agreement with an accredited investor to sell 578,387 shares of common stock and/or prefunded warrants, plus common warrants for up to 1,156,774 additional s...
Delistings and Listing ChangesRegulatory Filings and Compliance
ENDRA Life Sciences Faces Renewed Nasdaq Listing Compliance Risk
Negative
Apr 21, 2026
ENDRA Life Sciences disclosed a renewed compliance setback with Nasdaq’s stockholders’ equity requirements after previously regaining compliance in November 2025. Following a May 27, 2025 notice that equity had fallen below the $2.5 mi...
Business Operations and Strategy
ENDRA Life Sciences Explores Strategic Alternatives Amid Restructuring
Negative
Mar 25, 2026
On March 25, 2026, ENDRA Life Sciences said its board had begun a review of strategic alternatives to maximize shareholder value, retaining Lucid Capital Management as financial advisor and KL Gates as legal counsel. The board will consider option...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.